Revolution Medicines, Inc. (RVMD)
NEUTRALFundamental
36
Preço
$211.13
Capitalização de Mercado
$44.23B
Parte 1 · Quanto vale a empresa
Visão Geral
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
0
Exercício encerrado em 31/12/2025
Resultado Líquido
$-1.13B
Exercício encerrado em 31/12/2025
Fluxo de Caixa Livre
$-914M
Capital Próprio Total
$1.63B
Passivo Total
$723M
Rácio de Liquidez
11.38
Cobertura de Juros
27.42
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$223.24
Preço Atual
$211.13
Margem de Segurança
+5.4%
Intervalo de Valor Justo
$212.07 - $234.40
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-69.3%
Rácio P/B
17.40
P/FCF
-
Margem Bruta
-
ROIC
-32.4%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
-32.4%
WACC
12.0%
ROIC − WACC
-44.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (7)
- EPS shows upward trend
- Price CAGR 32.01%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 93% Buy
Reprovado (10)
- ROIC -32.4%
- P/B Ratio 17.40
- Operating Margin -Infinity%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -54.1%
- Earnings Surprise avg -25.1%
- Share Dilution 13.4%
- Piotroski F-Score 1/9
Indisponível (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A emitir novas ações, diluindo a participação
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Dr. Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman | 63 |
| Mr. Jack Anders | Chief Financial Officer | 48 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 62 |
| Mr. Jeffrey Cislini J.D. | Senior VP, General Counsel & Corporate Secretary | 50 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor | 64 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | - |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 44 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | - |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | - |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer | - |
Risco de Auditoria
2
Risco do Conselho
8
Risco de Remuneração
8
Risco dos Direitos dos Acionistas
8
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for RVMD, sourced from Markets Gazette.
- 6/1/2026POSITIVERevolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Revolution Medicines announced a significant breakthrough in pancreatic cancer treatment, with its experimental pill demonstrating a doubling of patient survival rates and a 60% reduction in the risk of death during clinical trials. This development is particularly noteworthy given the historically poor prognosis associated with pancreatic cancer. The positive trial results suggest a potential paradigm shift in treatment options for this aggressive disease. For investors, this news could translate into substantial future revenue streams and a re-evaluation of the company's growth prospects, especially as the stock is currently trading near its all-time highs.
- 4/13/2026POSITIVERevolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
Revolution Medicines Inc. stock surged following promising Phase 3 trial results for its pancreatic cancer drug, darsonvalrasib. The study demonstrated a doubling of survival rates compared to standard chemotherapy, a significant breakthrough for patients with KRAS G12C-mutated pancreatic cancer. The company announced plans for regulatory filings, signaling a clear path toward potential market approval. This development is highly encouraging for investors, suggesting a strong future revenue stream and a significant advancement in oncology treatment.
- 2/25/2026NEUTRALRevolution Medicines (RVMD) Earnings Transcript
Revolution Medicines (RVMD) has released its earnings transcript, although the specific content is not yet available for analysis. Investors are keenly awaiting the details of this publication, which could provide clarity on the company's financial performance and future outlook. The absence of immediate information prevents a directional assessment, keeping the stock in a holding pattern. It will be crucial to monitor the data as soon as it is disclosed to understand the impact on research and development, product pipeline, and market strategies, which are fundamental elements for evaluating RVMD's growth potential in the biopharmaceutical sector.
via Markets Gazette